---
schema_version: "secwatch.filing_event.v1"
accession: "0000885725-24-000040"
form_type: "8-K"
ticker: "BSX"
cik: "0000885725"
company_name: "BOSTON SCIENTIFIC CORP"
filed_at: "2024-04-24T23:59:59+00:00"
generated_at: "2026-06-03T10:52:58.501553+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Boston Scientific Q1 beats: $3.856B sales +13.8%, adj EPS $0.56 vs $0.50-0.52 guide; raises FY outlook

## Summary
- GAAP net income $495M ($0.33 EPS) vs guide $0.29-0.31; adjusted EPS $0.56 vs $0.47 YoY and $0.50-0.52 guide.
- Net sales $3.856B, +13.8% reported (guide 7.5-9.5%), +15.0% operational, +13.1% organic (guide 7-9%).
- Cardiovascular +15.9% reported, MedSurg +10.3%; U.S. +12.7%, APAC +18.3%, Emerging Markets +22.6%.
- Launched FARAPULSE PFA in U.S.; FDA approved AGENT Drug-Coated Balloon; €2.0B notes for Axonics acquisition.
- FY2024 guidance: sales growth 11-13% reported, 10-12% organic; adj EPS $2.29-2.34; Q2 adj EPS $0.57-0.59.

## SEC filing metadata
- accession: 0000885725-24-000040
- form_type: 8-K
- ticker: BSX
- cik: 0000885725
- company_name: BOSTON SCIENTIFIC CORP
- filed_at: 2024-04-24T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/885725/000088572524000040/0000885725-24-000040-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/885725/000088572524000040/bsx-20240424.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000885725-24-000040
- JSON: https://secwatch.observer/filing/0000885725-24-000040.json
- Plain text: https://secwatch.observer/filing/0000885725-24-000040.txt

## Key facts
- Earnings Releases
  BOSTON SCIENTIFIC CORP reported the first quarter ended March 31, 2024 results: revenue $3.856 billion, net income $495 million or $0.33 per share, EPS $0.56 for the period.
  - Period: the first quarter ended March 31, 2024
  - Revenue: $3.856 billion
  - Net income: $495 million or $0.33 per share
  - EPS: $0.56 for the period
  - Result: reported results
  source text: Document Boston Scientific Announces Results for First Quarter 2024 Marlborough, Mass. (April 24, 2024) -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.856 billion during the first quarter of 2024, growing 13.8 percent on a reported basis, 15.0 percent on an operational 1 basis and 13.1 percent on an organic 2 basis, all compared to the
  evidence_url: https://www.sec.gov/Archives/edgar/data/885725/000088572524000040/0000885725-24-000040-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.